Inhibrx Inc
NASDAQ:INBX
Inhibrx Inc
Net Income (Common)
Inhibrx Inc
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Inhibrx Inc
NASDAQ:INBX
|
Net Income (Common)
-$241.4m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$5.7B
|
CAGR 3-Years
258%
|
CAGR 5-Years
1%
|
CAGR 10-Years
6%
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$6.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
25%
|
See Also
What is Inhibrx Inc's Net Income (Common)?
Net Income (Common)
-241.4m
USD
Based on the financial report for Dec 31, 2023, Inhibrx Inc's Net Income (Common) amounts to -241.4m USD.
What is Inhibrx Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-51%
Over the last year, the Net Income (Common) growth was -66%. The average annual Net Income (Common) growth rates for Inhibrx Inc have been -47% over the past three years , -51% over the past five years .